Please browse our latest news, for information from around the firm and updates on our recent work.
For more information, please contact Orla O'Donovan, PR Manager.
Charles Russell Speechlys advises Kreos on growth capital investment in JenaValve Technologies, Inc.
Charles Russell Speechlys advised Kreos on its growth capital investment in a biotech company, JenaValve Technologies, Inc.
Charles Russell Speechlys advises Juno Health pharmacy group on its acquisition of the Avicenna Pharmacy group
Juno Health further establishes its position as one of the largest pharmacy chains in the Northeast of England.
Charles Russell Speechlys shortlisted for LaingBuisson Awards 2019
Charles Russell Speechlys has been selected as a finalist in the Legal Advisor – Independent category at LaingBuisson Awards 2019
Charles Russell Speechlys advises the Civica Group on the acquisition of occupational health cloud software specialist Warwick International Computing Systems
Warwick International provides specialist cloud software with a broad presence complementary to the Civica Group’s established activities.
Charles Russell Speechlys advises Country Court Care on acquisition of three care homes
Country Court Care has undergone rapid expansion over the last nine years.
Charles Russell Speechlys advises Vapotherm on the acquisition of Solus Medical
Vapotherm is a publicly traded developer and manufacturer of advanced respiratory technology.
Charles Russell Speechlys advises Kreos and SVB on £20m growth capital investment to Mereo BioPharma
We advised Kreos Capital and Silicon Valley Bank on the refinancing of £20 million growth capital investment to Mereo BioPharma Group
Kiadis Pharma secures €20 million debt financing facility from Kreos Capital
Charles Russell Speechlys advises Kreos Capital V Ltd on additional growth capital investment of €20 million in Kiadis Pharma NV
Charles Russell Speechlys advises Kreos Capital on €20 million growth capital facility in Medtech company
Charles Russell Speechlys have advised Kreos Capital on its additional growth capital facility of €20 million in Cellnovo Limited